Fludarabine
Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
Beijing BiotechSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Autologous Cd19/Cd22 Dual-Target Car-T Module Beijing Biotech | Phase 1/2 | CC |
Autologous Cd33/Cd123 Dual-Target Car-T Module Beijing Biotech | Phase 1/2 | CC |
Cyclophosphamide Beijing Biotech | Phase 1/2 | CC |
Autologous Cd19/Cd20 Dual-Target Car-T Module Beijing Biotech | Phase 1/2 | CC |
Autologous Bcma/Gprc5D Dual-Target Car-T Beijing Biotech | Phase 1/2 | CC |
View all 9 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →